Buy RU58841 Powder online

Description

High Purity Ru58841 Powder for sale

 

CAS Number	154992-24-2
Other Names	RU 58841, RU-58841, 0D8FJQ0ADW, CHEMBL9337, PSK-3841; HMR-3841, UNII-0D8FJQ0ADW
IUPAC Name	4-[3-(4-hydroxybutyl)-4,4-dimethyl-2,5-dioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile
Molecular Formula	C₁₇H₁₈F₃N₃O₃
Molecular Weight	369.34
Purity	≥99% Pure (LC-MS)
Application	Topical
Liquid Availability	30mL 5% KB solution
30mL 5% plant-based solution 30mL 8% KB solution 30mL 8% plant-based solution 60mL 5% KB solution
60mL 5% plant-based solution 60mL 8% KB solution 60mL 8% plant-based solution
Powder Availability	100 grams
Gel Availability	N/A
Storage	Store in cool dry environment, away from direct sunlight.
	Terms	All products are for laboratory developmental research USE ONLY.	Products are not for human consumption.

 

What is RU58841?

RU58841 is a topical (NSAA) hair solution that is used  for the treatment of androgenetic alopecia (male pattern baldness). It works by strongly competing against the hormone dihydrotestosterone (DHT) at the androgen receptor. Buy RU58841 Powder online

Preclinical Benefits Observed:
1. Targeted, localized therapy on the scalp with minimal systemic effects
2. Suppression of DHT for restoration of hair growth (ie. density, thickness, length)

Selected Preclinical Research:
1. “Evaluation of RU58841 as an anti-androgen in prostate cells and a topical anti-alopecia agent in the bald scalp of stumptailed macaques” [3]
The effect of androgen receptor transcriptional activation by RU58841, a nonsteroidal anti-androgen, was studied in the human prostate cancer cell line by and an androgen-responsive reporter construct. The anti-androgens hydroxyflutamide and Casodex, and the antiestrogen, genistein, were studied in parallel for comparison with RU58841. The Androgen Receptor was activated only by the androgen dihydrotestosterone (DHT). Neither the anti-androgens nor antiestrogen can enhance Androgen Receptor activity. Hydroxyflutamide, RU58841, and Casodex, but not genistein, displayed competitively suppressive effects on DHT activation of the Androgen Receptor. The potency of RU58841 was comparable to that of hydroxyflutamide. From this result, topical application of RU58841, which is considered to be a potential therapy for skin diseases, may induce systemic side effects. However, RU58841, on topical application, revealed a potent increase in density, thickening, and length of hair, whereas no systemic effects were detected. Together these results suggest that RU58841 may have potent antagonism to the Androgen Receptor and could be considered as a topically applied active anti-androgen for the treatment of androgen-dependent skin disorders, such as acne, and androgenetic alopecia. Buy RU58841 Powder online

Fig. 1. Folliculogram showing sequential patterns of the relative number of hairs at pretreatment (A) compared to 5 months after RU58841 treatment (B). At pretreatment, most hairs are in telogen phase (T) which is a resting state. However, after 5 months of RU58841 treatment, most hairs are in anagen phase (A5) which is a growth phase. Adapted from Pan et al., Endocrine 9(1):39-43.

This research demonstrated the effectiveness of RU58841 in promoting the hair density, hair thickening, and hair length in a primate model of alopecia relevant to humans. The authors note that RU58841 exerts a dose-dependent effect on follicular regrowth, and this observation indicates that RU58841 should be studied in the clinical setting for androgenic alopecia. The fact that topical application is effective stands in contrast to other antiandrogen such as cyproterone acetate which is inactive in human skin when applied topically. In addition to in vivo topical effects, RU58841 also antagonized testosterone-driven hair loss in vitro. Buy RU58841 Powder online

Fig. 2. Photographs showing effects of topical RU58841 on hair regrowth on bald frontal scalps. Increased density and length of hairs were observed in a scalp at 4 months after treatment with 5% RU 58841 (b) compared with the scalp at the pretreatment time (a). A slight increased density of hairs was noticed in a scalp at 4 months after treatment with 0.5% RU 58841 (d) compared with the scalp at the pretreatment time (c). A control-treated scalp showed no signs of hair regrowth (e) at pretreatment time compared to 4 months later (f). Adapted from Obana et al., Endocrinology 138(1) 356-361.